Credit: Shutterstock photoAffimed Therapeutics, an early-stage biotech developing immunotherapy antibodies to treat cancer, filed on Monday with the SEC to raise up to $75 million in an initial public offering. The Heidelberg, Germany-based company, which was founded in 2000 and booked $7 million in collaboration and service revenue for the 12 months ended March 31, 2014, plans to list on the NASDAQ under the symbol AFMD. Affimed Therapeutics initially filed confidentially on May 23, 2014. Jefferies, Leerink Partners and BMO Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
